COMBINED ANGIOGRAPHY MARKET

INTRODUCTION TOCOMBINED ANGIOGRAPHY MARKET

Cross-sectional imaging is an important technique in interventional radiology.

Despite the fact that cone-beam CT (CBCT) technology from flat-panel angiography systems has been established as an adjunct cross-sectional imaging tool during interventional procedures, the inherent advantages of angio-CT systems in terms of superior soft-tissue imaging and contrast resolution, as well as operational ease, have sparked renewed interest in their use in interventional oncology procedures.

 Angio-CT systems have become a viable alternative to stand-alone flat-panel angiographic systems integrated with CBCT due to advancements in price and usability as a result of enhanced workflow.

The goal of this study is to give a full technical and clinical guide for using angio-CT systems in interventional oncology. The fundamental ideas behind the usage of angio-CT systems, including workflow setup, imaging properties, and acquisition.

An overview of the clinical uses and advantages of angio-CT systems in routine therapeutic and palliative interventional cancer treatments will also be provided. Patients having transcatheter aortic valve implantation (TAVI) frequently have significant coronary artery disease (CAD).

Current recommendations propose assessing CAD prior to TAVI, which is mostly done by invasive coronary angiography (ICA). The potential of coronary CT-angiography (cCTA) to rule out severe CAD during routine pre-TAVI examination in individuals with a high pretest likelihood for CAD was investigated in this research.

 A retrospectively ECG-gated CT-scan of the heart was performed on all patients, followed by a high-pitch scan of the vascular access route using a single intravenous bolus of 70 ml iodinated contrast media. 

Images were examined for image quality, calcifications, and severe CAD; CT-examinations that could not be ruled out for CAD were classified as positive (CAD+). Patients were routinely given ICA, which was skipped if renal function was deteriorated and CAD was ruled out on cCTA (Group B). Clinical events were reported during the hospital stay following TAVI.

 respectively. The median coronary artery calcium score (CAC) was greater in CAD patients but had no predictive value for proper cCTA categorization. There were no statistically significant differences in clinical outcomes between Groups A and B.

cCTA can be used in pre-TAVI CT evaluations without the use of extra contrast media. In a reasonably high percentage of these high-risk individuals, cCTA may rule out severe CAD.

To show the viability of a novel noninvasive MRI approach for assessing blood flow to the brain: combined angiography and perfusion utilizing radial imaging and arterial spin labeling (CAPRIA).

Using a golden ratio radial readout, blood labeled with a pseudo continuous arterial spin labeling pulse train is constantly observed as it travels through the arterial tree and into brain tissue in the CAPRIA pulse sequence.

This flexible imaging method permits the reconstruction of both high spatial/temporal resolution angiographic pictures with a high undersampling factor and low spatial/temporal resolution perfusion images with a low undersampling factor from a single raw data set.

Because angiographic pictures are sparse and have a high SNR, radial undersampling artifacts are largely benign, even when employing a high-resolution camera.The sampling efficiency estimates and numerical assessment of modified pseudocontinuous arterial spin labeling signal models were used to optimize the pulse sequence parameters. The results were compared to standard pseudocontinuous arterial spin labeling angiographic and perfusion acquisitions.

When rebuilt at 108-ms and 252-ms temporal resolutions, 2D CAPRIA data from healthy participants proved the viability of this method, with good vessel visualization in the angiographic pictures and obvious tissue perfusion signal. Images from traditional acquisitions were qualitatively identical, but CAPRIA had considerably greater SNR efficiency. 

The CAPRIA approach has the ability to efficiently assess both microvascular blood flow and tissue perfusion in a single scan, with applications in a variety of cerebrovascular disorders.

COMBINED ANGIOGRAPHY MARKET  SIZE AND FORECAST

The Global Combined Angiography Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

COMBINED ANGIOGRAPHY MARKETNEW PRODUCT LAUNCH

Royal Philips (NYSE: PHG, AEX: PHIA), a worldwide pioneer in health technology, announced its vision for interventional medicine today by incorporating its groundbreaking spectral CT imaging technology into a hybrid Angio CT suite.

Philips hopes to give interventionalists immediate table-side access to these two key imaging modalities by combining the company's unique Spectral CT 7500 system and its Image-Guided Therapy System - Azurion with FlexArm in a single interventional suite solution, allowing them to perform procedures requiring both CT and angio guidance in one room. Philips is working together with a major clinical center to create this integrated solution.

The purpose of merging the groundbreaking, first-of-its-kind Spectral CT 7500 with the Azurion platform is to create a seamless working environment. The relevant imaging modalities are available immediately at the patient table and are completely controlled from the table-side work area.

When not in use, each modality slides easily away from the patient table into a parking position, allowing the interventional team unfettered access to the patient. If necessary, each system can operate independently.

It allows interventionalists to create efficient workflows without having to relocate patients from one imaging suite to another. For patients, this implies that their doctors may use both systems' strengths during a single procedure.

Philips' always-on spectral CT technology enables improved detection, delineation, and quantification of lesions, leading to better-informed planning for minimally invasive procedures by requiring only one scan to capture all of the spectral information required to differentiate and quantify different tissues.

THIS REPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many   Combined Angiographies    are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global  Combined Angiography    and key vendor selection criteria
3. Where is the  Combined Angiography   manufactured? What is the average margin per unit?
4. Market share of Global  Combined Angiography    market  manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global  Combined Angiography    in-house
6. 5 key predictions for next 5 years in Global  Combined Angiography    market
7. Average B-2-B   Combined Angiography  market price in all segments
8. Latest trends in   Combined Angiography  market, by every market segment
9. The market size (both volume and value) of the   Combined Angiography    market in 2024-2030 and every year in between?
10. Production breakup of   Combined Angiography    market, by suppliers and their OEM relationship